Redx Pharma appoints Dr Jane Robertson as Chief Medical Officer

pharmafile | October 29, 2020 | Appointment | Research and Development  

Redx Pharma has announced the appointment of Dr Jane Robertson as its new Chief Medical Officer at the company.

Robertson joins the company after previously serving as the CMO of Achilles Therapeutics. Before joining Achilles, she was also the CMO at Nucana Biomed Ltd and at Kesios Therapeutics Ltd. She has also held a number of senior roles in R&D at AstraZeneca Oncology.

Lisa Anson, Chief Executive Officer of Redx Pharma, commented: “We are absolutely delighted that Jane has chosen to join our team at this exciting stage in Redx’s development.  As our Chief Medical Officer, her extensive and varied experience in big pharma, biotech and clinical practice, will be invaluable as we further progress our pipeline into clinical development.”

Robertson will replace Dr Andrew Saunders who will leave the company after 3 years as CMO. Lisa Anson said of his departure: “On behalf of all of Redx and the Board, I would like to thank Andrew for his great work in overseeing the transition of RXC004 into phase 1 and his strategic guidance in our planned future development plans for RXC004.”

In terms of education, Robertson received a Bachelors in Physiological Sciences from Oxford, a Bachelor of Medicines, Bachelor of Surgery from University of London, and a Doctor of Medicine from the University of Manchester.

Related Content

No items found

Latest content